KYLYS Aesthetics secures CHF 1 M to advance next-gen hyaluronic acid medical devices
23.06.2025
Geneva-based KYLYS Aesthetics, focused on regenerative aesthetic solutions, has raised CHF 1 Million to accelerate the development and clinical validation of its patented hyaluronic acid-based Class III medical device.
 |
 |
KYLYS Aesthetics develops innovative injectable products designed for soft tissue regeneration and rejuvenation. Its flagship device, created with the University of Geneva, aims to deliver safer and longer-lasting results.
The CHF 1 Million funding round involved new and existing investors, including Fongit and The Berlin Angel Fund. The capital will support clinical trials, regulatory approvals, and product development.
Supported by Swiss innovation programs and research institutions, KYLYS, Venture Kick winner and Venture Leaders Biotech past participant, is now well-positioned to bring its next-generation medical devices to market.
Eric Allémann, Alexandre and Bryan Porcello, and Olivier Jordan
The CHF 1 Million funding round involved new and existing investors, including Fongit and The Berlin Angel Fund. The capital will support clinical trials, regulatory approvals, and product development.
Supported by Swiss innovation programs and research institutions, KYLYS, Venture Kick winner and Venture Leaders Biotech past participant, is now well-positioned to bring its next-generation medical devices to market.
Eric Allémann, Alexandre and Bryan Porcello, and Olivier Jordan